Clinical trials: Injectables
Gene Expression
Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler
To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy
- Trial name
- Sculptra (NCT05620043)
- Testing
- Sculptra, Radiesse Plus
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Lip Augmentation
Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation
The purpose of this study is to demonstrate the safety and effectiveness of Juvederm(R) Ultra XC Injectable Gel for lip augmentation
- Trial name
- NCT01197495
- Testing
- hyaluronic acid gel
- Where
- United States
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Allergan
Contraception
Pharmacokinetic and Pharmacodynamic Study of Cyclofem
Cyclofem® is a monthly injectable contraceptive containing 25 mg of medroxyprogesterone acetate (MPA) and 5 mg of estradiol cypionate (E2C), a long-acting ester of estradiol.
- Trial name
- NCT01699022
- Testing
- Injection Cyclofem
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries Limited
Schizophrenia, Psychotic Disorders
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine…
- Trial name
- NCT00216476
- Testing
- Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine
- Where
- 96 sites in Austria, Bulgaria and 22 more
- Volunteers
- 753 people
- Sponsor
- Janssen-Cilag International NV
Opioid Use Disorder, Chronic Pain
Phase II Pharmacokinetics Study of CAM2038
Phase II, open label, partially randomized, three treatment group study designed to evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine following repeated subcutaneous administrations of CAM2038.
- Trial name
- NCT02710526
- Testing
- CAM2038
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Braeburn Pharmaceuticals
Opioid Use Disorder
Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
This study will evaluate the safety, effectiveness and tolerance of low doses of oral naltrexone along with buprenorphine to treat opioid use disorder prior to the first injection of VIVITROL.
- Trial name
- NCT02537574
- Testing
- NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
- Where
- 20 sites in United States
- Volunteers
- 380 people
- Sponsor
- Alkermes, Inc.
Temple Hollowing
Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing
This study will evaluate the safety and effectiveness of JUVÉDERM VOLUMA XC injectable gel in adult participants seeking correction of temple hollowing.
- Trial name
- NCT03166618
- Testing
- Juvéderm® VOLUMA XC
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Allergan
Aesthetic Dermatology
Safety and Effectiveness Clinical Evaluation of Injectable Medical Devices
The study aims to confirm the safety and effectiveness of FILLGEL devices
- Trial name
- NCT06142578
- Testing
- Dermal Filler Device
- Where
- Switzerland
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Kylane Laboratoires
Wrinkles
Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds
The purpose of this study is to see how well Juvederm Ultra XC or Juvederm Ultra Plus XC, and BOTOX Cosmetic, work compared to each other and when used together for the cosmetic treatment of age-associated wrinkles and folds of…
- Trial name
- JUVE_BTX (NCT01269801)
- Testing
- onabotulinumtoxinA, JUVÉDERM
- Where
- 3 sites in United States, Canada
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- AboutSkin Dermatology and DermSurgery, PC
Infraorbital Hollowing
A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing
The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM® VOLBELLA™ XC in adult participants seeking correction of hollowing of the tear troughs.
- Trial name
- NCT03418545
- Testing
- JUVÉDERM VOLBELLA® XC injectable gel
- Where
- 15 sites in United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Schizophrenia
A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
A study to determine the maximum tolerated dose of an investigational drug in subjects with schizophrenia
- Trial name
- NCT03627195
- Testing
- DSP-1349M
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sumitomo Pharma America, Inc.
Mid-facial Volume Deficit Related to Aging
Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation
Multicenter, single-blind, randomized, "no-treatment" control study to demonstrate the safety and effectiveness of VOLUMA XC for deep injection for cheek augmentation to correct age-related volume deficit in the mid-face.
- Trial name
- NCT00978042
- Testing
- Juvéderm® VOLUMA XC
- Where
- 2 sites in United States, Canada
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Allergan
Age-related Volume Deficit in the Mid-face
A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula
The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM VOLUMA® XC injectable gel using cannula in participants seeking correction of age-related volume deficit in the mid-face.
- Trial name
- NCT03438266
- Testing
- JUVÉDERM VOLUMA® XC injectable gel with cannula, JUVÉDERM VOLUMA® XC injectable gel with needle
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Allergan
Uveitis, Uveitis, Posterior
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- AZALEA (NCT03097315)
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 10 sites in United States
- Volunteers
- 38 people
- Sponsor
- Clearside Biomedical, Inc.
Myelodysplastic Syndromes
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason…
- Trial name
- NCT02281084
- Testing
- Oral Azacitidine, Durvalumab
- Where
- 89 sites in United States, Australia and 8 more
- Volunteers
- 65 people
- Sponsor
- Celgene
Pneumonia
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
Part 1 of this trial enrolled 30 patients to receive Auxora (formerly CM4620) in a 2:1 randomized, open label trial of patients with severe and critical COVID-19 pneumonia.
- Trial name
- NCT04345614
- Testing
- Auxora (Part 1), Standard of Care (Part 1), Auxora (Part 2)
- Where
- 17 sites in United States
- Volunteers
- 314 people
- Sponsor
- CalciMedica, Inc.
Uveitis, Uveitis, Posterior
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Intermediate
- Trial name
- NCT05070728
- Testing
- FAI Insert
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Organ Transplant Rejection, Psoriasis
Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study
This first-in-human study is designed to assess the safety and pharmacokinetic (PK) profile of sustained-release (SR) depot tacrolimus, which will be administered as a single dose of 0.1 mg/kg by subcutaneous (SC) injection in…
- Trial name
- NCT03626714
- Testing
- Sustained Release Injectable Tacrolimus
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Auritec Pharmaceuticals
Schizophrenia
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.
- Trial name
- NCT00589914
- Testing
- RISPERDAL CONSTA, Paliperidone palmitate
- Where
- 82 sites in United States, Austria and 12 more
- Volunteers
- 1,221 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode
The primary objective of this randomized trial was to investigate whether early initiation of treatment with Risperdal Consta after an acute episode was not inferior to the routine approach (oral treatment for 12 weeks followed…
- Trial name
- NCT00216671
- Testing
- early initiation of treatment with Risperdal Consta, routine initiation of treatment with Risperdal Consta
- Where
- 31 sites in Denmark, Finland and 8 more
- Volunteers
- 220 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium